About PrevEp
PrevEp is a Healthcare company based in Bethesda (United States) founded in 2018 by Chris Rundfeldt, Wolfgang Loscher, Detlev Boison, Alexander Rotenberg, Pavel Klein, and Matthias Koepp. Therapeutics for preventing epilepsy after brain injury are developed. PrevEp offers products and services including Seletracetam Nasal Spray and Intravenous Topiramate. Its focus areas include Life Sciences, Neurology, Drugs and Epilepsy. Its competitors include Marinus Pharma, Epygenix and GenEp; 2 of its 3 listed competitors have raised funding.
Company details
PrevEp was founded in 2018 and is headquartered in Bethesda, United States. Therapeutics are developed by the company for the treatment of neurological diseases, with a focus on drug candidates that block epileptogenesis following acquired brain injury. Operations center on advancing preventive solutions for epilepsy in the biotechnology sector, involving co-founders with expertise in neurology and pharmacology.
- Headquarters Bethesda, United States
- Founders Chris Rundfeldt, Wolfgang Loscher, Detlev Boison, Alexander Rotenberg, Pavel Klein, Matthias Koepp
- SectorsHealthcare
- Website prevep.com
- Latest Funding Round$702.51K (USD), Grant
Sep 2023
- Investors
Products & Services of PrevEp
PrevEp offers a comprehensive portfolio of products and services, including Seletracetam Nasal Spray and Intravenous Topiramate.
Nasal formulation for safe treatment of acute repetitive seizures.
Injectable drug to suppress neonatal seizures when other options fail.
Funding Insights of PrevEp
- Total Rounds 2
- Last Round Grant — $702,512
- First Round $700,003
(Sep 2021)
- Investors Count 1
All 2 funding rounds of PrevEp with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
1 investors in total: 1 institutional.
Investors in PrevEp
PrevEp has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for PrevEp
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of PrevEp
6 people are tracked at PrevEp (6 in leadership).
| Name | Role | Group |
|---|---|---|
Chris Rundfeldt | Co-Founder | Leadership |
Wolfgang Loscher | Co-Founder | Leadership |
Detlev Boison | Co-Founder | Leadership |
Alexander Rotenberg | Co-Founder | Leadership |
Pavel Klein | Co-Founder | Leadership |
Matthias Koepp | Co-Founder | Leadership |
Complete people profiles for PrevEp
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of PrevEp
3 dated milestones of PrevEp across 5 years, from founding to its latest funding, stage changes and deals.
- Founded PrevEp is founded.
- Funding First funding round of $700K.
- Funding Latest funding round, Grant, of $703K.
Competitors of PrevEp
PrevEp has 3 listed competitors in our database, 2 of them funded. They include Marinus Pharma, Epygenix and GenEp.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| marinuspharma.com | 2003 | Radnor, United States | $71.58M | 114 | Developer of therapeutics to treat seizure disorders | |
| epygenix.com | 2016 | Paramus, United States | Develops drugs for rare neurological disorders including sleep, neurobehavioral, and epilepsy conditions. | |||
| genepbio.com | 2021 | Charlottesville, United States | $10.4M | Therapeutics for epilepsy are developed targeting ion channel mutations. |
Detailed competitors of PrevEp
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Neurology
3 companies that operate in the same segment as PrevEp (Neurology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about PrevEp
PrevEp was founded in 2018 and raised its 1st funding round 3 years after it was founded.
PrevEp is headquartered in Bethesda, United States. It is registered at Bethesda, Maryland, United States.
PrevEp was founded in 2018 and is headquartered in Bethesda, United States. Therapeutics are developed by the company for the treatment of neurological diseases, with a focus on drug candidates that block epileptogenesis following acquired brain injury. Operations center on advancing preventive solutions for epilepsy in the biotechnology sector, involving co-founders with expertise in neurology and pharmacology.
PrevEp's top competitors include Marinus Pharma, GenEp and Epygenix.
PrevEp offers Seletracetam Nasal Spray and Intravenous Topiramate.
PrevEp has 1 investor. Key investors include HHS.